Smith & Nephew's $22 billion talks with J&J's orthopaedics unit collapse over CEO dispute
Smith & Nephew's late-stage merger talks with J&J's orthopaedics unit, valued at up to $22 billion, collapsed over the leadership of the combined company.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, Smith & Nephew held late-stage merger talks with Johnson & Johnson's orthopaedics unit, a business valued at up to $22 billion. The talks collapsed over a disagreement about who would serve as chief executive of the combined company.
Smith & Nephew refused to have former CEO Namal Nawana lead the merged firm and insisted that current CEO Deepak Nath remain in charge.
TradingView notes that the text is an AI-generated summary that may contain inaccuracies, so important details should be verified with the original sources.
why it matters
For investors, the collapse of a deal this large means Smith & Nephew's planned portfolio reshaping is on hold, and uncertainty over the company's leadership remains. For J&J, the failed sale leaves the structure of its orthopaedics business unchanged.
market impact
Smith & Nephew shares and medtech sector: the collapse removes expectations of a large merger
tags
instruments
sources
- Key facts: Smith & Nephew (SN) $22B J&J Deal Collapses; CEO Dispute — TradingView, 24 October 2026 at 07:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗